See more : NeutriSci International Inc. (NRXCF) Income Statement Analysis – Financial Results
Complete financial analysis of Wockhardt Limited (WOCKPHARMA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wockhardt Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ibere Pharmaceuticals (IBER) Income Statement Analysis – Financial Results
- DP Cap Acquisition Corp I (DPCS) Income Statement Analysis – Financial Results
- Butler National Corporation (BUKS) Income Statement Analysis – Financial Results
- Avance Technologies Limited (AVANCE.BO) Income Statement Analysis – Financial Results
- United Breweries Limited (UBL.NS) Income Statement Analysis – Financial Results
Wockhardt Limited (WOCKPHARMA.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.wockhardt.com
About Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.89B | 26.51B | 32.10B | 26.99B | 28.33B | 41.40B | 39.37B | 40.15B | 44.61B | 44.82B | 48.30B | 56.09B | 46.14B | 37.51B | 45.01B | 35.93B | 26.53B | 17.29B | 14.13B |
| Cost of Revenue | 20.17B | 11.11B | 12.67B | 11.35B | 12.03B | 18.15B | 17.98B | 16.62B | 16.04B | 14.87B | 18.06B | 17.48B | 18.38B | 15.16B | 19.73B | 13.40B | 9.93B | 6.68B | 5.77B |
| Gross Profit | 7.72B | 15.40B | 19.43B | 15.64B | 16.30B | 23.25B | 21.39B | 23.53B | 28.57B | 29.94B | 30.24B | 38.62B | 27.76B | 22.35B | 25.29B | 22.52B | 16.60B | 10.61B | 8.36B |
| Gross Profit Ratio | 27.68% | 58.09% | 60.53% | 57.93% | 57.52% | 56.17% | 54.34% | 58.60% | 64.04% | 66.81% | 62.61% | 68.85% | 60.17% | 59.58% | 56.18% | 62.69% | 62.58% | 61.37% | 59.16% |
| Research & Development | 1.32B | 1.41B | 1.43B | 1.72B | 2.08B | 2.91B | 2.87B | 3.97B | 9.96B | 4.89B | 4.03B | 8.27B | 537.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.05B | 1.10B | 1.48B | 1.35B | 1.02B | 2.24B | 2.69B | 3.03B | 2.06B | 1.40B | 795.70M | 1.02B | 2.67B | 0.00 | 0.00 | 0.00 | 0.00 | 116.95M | 89.92M |
| Selling & Marketing | 1.25B | 1.34B | 1.80B | 1.32B | 1.41B | 2.39B | 2.09B | 2.05B | 2.59B | 2.62B | 2.93B | 2.92B | 2.12B | 0.00 | 0.00 | 0.00 | 0.00 | 1.07B | 830.79M |
| SG&A | 2.30B | 2.44B | 3.28B | 2.67B | 2.44B | 4.62B | 4.78B | 5.08B | 4.65B | 4.02B | 3.73B | 3.94B | 4.80B | 0.00 | 0.00 | 0.00 | 0.00 | 1.18B | 920.71M |
| Other Expenses | 0.00 | 14.46B | 15.64B | 15.78B | 15.12B | 24.20M | 231.30M | 103.60M | 20.17B | 19.11B | 18.12B | 15.01B | 9.12B | 1.37B | -527.60M | -1.30B | 10.89B | 9.55B | 7.16B |
| Operating Expenses | 16.24B | 16.90B | 18.92B | 18.45B | 17.56B | 23.56B | 23.44B | 24.75B | 24.82B | 23.12B | 21.84B | 18.94B | 14.46B | 14.27B | 18.24B | 15.16B | 10.89B | 10.74B | 8.08B |
| Cost & Expenses | 28.65B | 28.01B | 31.59B | 29.80B | 29.59B | 41.71B | 41.42B | 41.37B | 40.86B | 38.00B | 39.90B | 36.42B | 32.84B | 29.43B | 37.97B | 28.57B | 20.82B | 17.42B | 13.85B |
| Interest Income | 60.00M | 40.00M | 60.00M | 205.60M | 99.90M | 175.40M | 293.10M | 633.50M | 446.40M | 79.80M | 97.50M | 308.10M | 96.40M | 38.50M | -470.33M | 112.70M | 0.00 | 284.43M | 248.73M |
| Interest Expense | 3.05B | 3.02B | 2.82B | 2.43B | 2.70B | 2.60B | 2.47B | 2.18B | 906.80M | 537.00M | 828.50M | 1.84B | 2.14B | 2.67B | 2.95B | 2.70B | 1.64B | 409.35M | 261.26M |
| Depreciation & Amortization | 2.23B | 2.51B | 2.47B | 2.46B | 2.24B | 1.64B | 1.50B | 1.49B | 1.43B | 1.45B | 1.40B | 1.25B | 1.23B | 1.17B | 1.55B | 1.19B | 839.73M | 620.61M | 426.23M |
| EBITDA | 1.08B | -710.00M | 1.35B | -733.80M | 1.57B | -201.70M | -2.42B | 1.24B | 5.60B | 8.27B | 9.80B | 20.87B | 9.14B | 4.88B | 8.60B | 8.33B | 6.56B | 3.94B | 3.62B |
| EBITDA Ratio | 3.87% | 8.41% | 9.38% | -0.75% | 4.68% | 3.01% | 1.17% | 1.98% | 12.51% | 16.65% | 22.03% | 37.21% | 31.69% | 24.65% | 19.10% | 23.95% | 24.71% | 26.46% | 25.70% |
| Operating Income | -300.00M | -280.00M | 540.00M | -2.66B | -931.70M | -310.90M | -2.05B | -1.23B | 3.76B | 6.82B | 8.40B | 19.67B | 13.30B | 8.08B | 7.05B | 7.36B | 5.72B | -125.24M | 279.10M |
| Operating Income Ratio | -1.08% | -1.06% | 1.68% | -9.87% | -3.29% | -0.75% | -5.21% | -3.06% | 8.42% | 15.21% | 17.39% | 35.07% | 28.83% | 21.54% | 15.65% | 20.49% | 21.54% | -0.72% | 1.98% |
| Total Other Income/Expenses | -3.90B | -6.24B | -4.65B | -5.68B | -2.20B | -2.55B | -4.36B | -1.24B | -780.70M | -1.06B | 507.60M | -1.31B | -7.53B | -7.07B | -16.90B | -9.64B | -974.29M | 3.03B | 2.67B |
| Income Before Tax | -4.20B | -6.24B | -4.11B | -5.68B | -3.42B | -3.00B | -6.41B | -2.47B | 3.57B | 5.75B | 8.91B | 18.38B | 5.77B | 1.04B | -9.86B | -2.51B | 4.74B | 2.94B | 2.95B |
| Income Before Tax Ratio | -15.06% | -23.54% | -12.80% | -21.06% | -12.07% | -7.25% | -16.29% | -6.16% | 8.00% | 12.84% | 18.44% | 32.76% | 12.50% | 2.78% | -21.90% | -6.99% | 17.87% | 17.01% | 20.84% |
| Income Tax Expense | 520.00M | -30.00M | -1.32B | -2.72B | -2.04B | -836.60M | 257.00M | -211.10M | 254.80M | 1.63B | 478.80M | 2.58B | 2.35B | 86.47M | 166.67M | 916.22M | 916.58M | -529.22M | -374.06M |
| Net Income | -4.63B | -6.21B | -2.79B | -2.97B | -1.38B | -1.95B | -6.08B | -1.96B | 3.26B | 4.05B | 8.41B | 15.95B | 3.43B | 905.19M | -10.01B | -1.39B | 3.86B | 3.47B | 3.32B |
| Net Income Ratio | -16.60% | -23.43% | -8.69% | -10.99% | -4.87% | -4.70% | -15.45% | -4.88% | 7.30% | 9.04% | 17.40% | 28.43% | 7.43% | 2.41% | -22.23% | -3.87% | 14.54% | 20.07% | 23.49% |
| EPS | -32.05 | -43.11 | -23.14 | -24.69 | -11.48 | -16.20 | -50.69 | -16.32 | 20.93 | 33.92 | 70.63 | 134.18 | 28.85 | 7.62 | -84.26 | -11.69 | 32.48 | 20.32 | 21.70 |
| EPS Diluted | -32.10 | -43.11 | -23.14 | -24.69 | -11.48 | -16.12 | -50.10 | -16.13 | 20.78 | 33.53 | 69.77 | 132.09 | 28.71 | 7.62 | -84.26 | -11.69 | 32.48 | 20.31 | 21.68 |
| Weighted Avg Shares Out | 144.46M | 144.06M | 120.56M | 120.18M | 120.15M | 120.09M | 119.99M | 119.95M | 119.79M | 119.36M | 119.03M | 118.80M | 118.76M | 118.76M | 118.76M | 118.76M | 118.76M | 118.74M | 118.46M |
| Weighted Avg Shares Out (Dil) | 144.25M | 144.06M | 120.56M | 120.18M | 120.15M | 120.71M | 121.41M | 121.32M | 120.66M | 120.73M | 120.50M | 120.68M | 119.35M | 118.76M | 118.76M | 118.76M | 118.76M | 118.76M | 118.59M |
Source: https://incomestatements.info
Category: Stock Reports